Kura Oncology (KURA) Gains from Sales and Divestitures (2014 - 2025)

Kura Oncology (KURA) reported Gains from Sales and Divestitures of $401000.0 for Q4 2025, up 208.46% quarter-over-quarter from $130000.0 in Q4 2018.

Kura Oncology (KURA) Gains from Sales and Divestitures (2014 - 2025) Analysis & Trends

Kura Oncology (KURA) has 6 years of Gains from Sales and Divestitures data on file, last reported at $401000.0 in Q4 2025.

Gains from Sales and Divestitures for Q4 2025 came in at $401000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $401000.0 (changed N/A YoY), and the FY2025 annual result was $401000.0, changed N/A from the prior year.
Gains from Sales and Divestitures rose to $401000.0 in Q4 2025 per KURA's latest filing, from $130000.0 in the prior quarter.
Over five years, Gains from Sales and Divestitures peaked at $401000.0 in Q4 2025 and troughed at $401000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Kura Oncology	883.44 Mn	883.44 Mn	18.00 Mn

Download Data